Re­gen­eron teams with gene ther­a­py pi­o­neer James Wil­son, adapt­ing its Covid-19 an­ti­body cock­tail to an AAV-based nasal spray

Gene ther­a­py pi­o­neer James Wil­son is ap­ply­ing his knowl­edge and ex­pe­ri­ence in the field to a new fron­tier: the Covid-19 pan­dem­ic.

Wil­son and his col­leagues at the Uni­ver­si­ty of Penn­syl­va­nia have signed a col­lab­o­ra­tion agree­ment with an­ti­body star Re­gen­eron $REGN to com­bine the biotech’s Covid-19 an­ti­body cock­tail with a nasal spray-based AAV de­liv­ery plat­form. The re­search could hit the clin­ic ear­ly next year, with the pair aim­ing to ap­ply for an IND af­ter val­i­dat­ing the an­ti­bod­ies’ ef­fec­tive­ness in an an­i­mal mod­el chal­lenge study.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER